Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
Metastasis02:30

Metastasis

Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
Cancer Cell Migration through Invadopodia01:35

Cancer Cell Migration through Invadopodia

Invadosome is a broad category of cell surface structures with proteolytic activity that  degrades the extracellular matrix (ECM). Invadosomes are present in normal cell types, including macrophages, endothelial cells, and neurons, as well as tumor cells. Although the macrophage podosomes and tumor cell invadopodia are classified as invadosomes, they have different structures, molecular pathways, and functions. Podosomes are short structures that last for a few minutes. However, invadopodia can...
Selectins01:25

Selectins

Cell adhesion is  an essential aspect of multicellularity. While stable cell interactions usually occur between cells of the same type, transient cell interactions occur between cells of different tissue types, such as between neutrophils and endothelial cells. Selectins are one class of cell adhesion molecules (CAMs) that bind carbohydrate ligands to form transient cell adhesion. They are rod-like proteins with a long extracellular part of variable length ending with the lectin domain, which...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Upper Extremity Deep Vein Thrombosis in Cancer Patients: Clinical Course by Cancer Site.

JACC. CardioOncology·2026
Same author

Peripartum Vascular Calamities: Placental Abruption and Amniotic Fluid Emboli.

Seminars in thrombosis and hemostasis·2026
Same author

Outcomes and predictors of complications after distal deep vein thrombosis: a prospective analysis of 8488 patients.

Journal of thrombosis and haemostasis : JTH·2026
Same author

Maximizing photon utilization in spectroscopic single-molecule localization microscopy using symmetrically dispersed dual-wedge prisms.

Npj imaging·2026
Same author

Platelet and Fibrinogen Dynamics After CAR-T Cell Therapy in Relapsed/Refractory B-Cell Lymphoma May Predict ICANS Onset.

European journal of haematology·2026
Same author

Challenges in Balancing Hemostasis and Thrombosis in Therapy Tailoring for Hemophilia: A Narrative Review.

International journal of molecular sciences·2026

Related Experiment Video

Updated: Jul 3, 2026

Extracellular Vesicle Tissue Factor Activity Assay
03:53

Extracellular Vesicle Tissue Factor Activity Assay

Published on: December 29, 2023

Heparanase, tissue factor, and cancer.

Yona Nadir1, Israel Vlodavsky, Benjamin Brenner

  • 1Thrombosis and Hemostasis Unit, Department of Hematology, Rambam Medical Center, Haifa, Israel. ynadir@netvision.net.il

Seminars in Thrombosis and Hemostasis
|July 23, 2008
PubMed
Summary

Heparanase enzyme promotes cancer spread and blood clots by increasing tissue factor (TF) and tissue factor pathway inhibitor (TFPI). Heparin

Area of Science:

  • Biochemistry
  • Oncology
  • Hematology

Background:

  • Heparanase is an enzyme that degrades heparan sulfate.
  • Heparanase activity is linked to cancer metastasis and angiogenesis.
  • Heparanase influences coagulation factors.

Purpose of the Study:

  • To investigate the role of heparanase in regulating tissue factor (TF) and tissue factor pathway inhibitor (TFPI).
  • To explore the mechanisms by which heparanase affects TF and TFPI levels.
  • To assess the implications for heparanase-targeted therapies.

Main Methods:

  • Overexpression of heparanase in cancer cell lines and transgenic mice.
  • Treatment of cells with recombinant heparanase.
  • Measurement of TF and TFPI levels and activity.

More Related Videos

Phospholipid Mediator Induced Transformation in Three-Dimensional Cultures
08:02

Phospholipid Mediator Induced Transformation in Three-Dimensional Cultures

Published on: July 27, 2022

Three-Dimensional (3D) Tumor Spheroid Invasion Assay
12:19

Three-Dimensional (3D) Tumor Spheroid Invasion Assay

Published on: May 1, 2015

Related Experiment Videos

Last Updated: Jul 3, 2026

Extracellular Vesicle Tissue Factor Activity Assay
03:53

Extracellular Vesicle Tissue Factor Activity Assay

Published on: December 29, 2023

Phospholipid Mediator Induced Transformation in Three-Dimensional Cultures
08:02

Phospholipid Mediator Induced Transformation in Three-Dimensional Cultures

Published on: July 27, 2022

Three-Dimensional (3D) Tumor Spheroid Invasion Assay
12:19

Three-Dimensional (3D) Tumor Spheroid Invasion Assay

Published on: May 1, 2015

  • Analysis of p38 phosphorylation.
  • Demonstration of physical interaction between heparanase and TFPI.

    • Main Results:

    • Heparanase overexpression or addition increased TF levels and procoagulant activity.
    • Heparanase induced TF via p38 phosphorylation.
    • Heparanase overexpression or addition increased TFPI expression and accumulation.
    • A physical interaction between heparanase and TFPI was observed, leading to TFPI dissociation from cell membranes.
    • Heparanase's effect on TFPI appeared independent of its enzymatic activity.

    Conclusions:

    • Heparanase plays a significant role in regulating the TF/TFPI pathway.
    • Heparanase promotes a prothrombotic state, contributing to cancer progression.
    • Heparins, as heparanase inhibitors, may have expanded therapeutic potential beyond anticoagulation.